P-D1 (Tanzania)
|
2 mo. at start of study
|
Weekly for one year
|
One year after termination of treatment
|
Reduced incidence of clinical malaria by 40% during treatment period
|
80% higher incidence of clinical episodes in treated group during the year following termination of treatment
|
[17]
|
P-D (The Gambia)
|
3 mo. at start of study
|
Every 2 weeks for maximum of 5 years
|
5 years
|
65% reduction in malaria episodes after 3 years of chemoprophylaxis
|
52% more cases in treated group during the year following termination of treatment
|
[18, 22]
|
SP2 + artesunate (The Gambia)
|
Entire villages, all ages
|
MDA3 1 dose
|
20 weeks
|
Reduced rate of malaria attacks in children <11 yr by 60%
|
Rate of clinical malaria was 69% higher in treated groups 3 months after treatment
|
[25]
|
SP (Mali)
|
3 mo. to 20 years
|
MDA 1 dose
|
24 weeks
|
Reduced incidence of first malaria episode from 26% to 3% during first month
|
Incidence of first malaria episodes in treated group rose to 42% compared to 17% (untreated group) during the third month after treatment
|
[26]
|